Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEP Regimen with Radiotherapy in Recurrent Nasopharyngeal Carcinoma
NCT06611826Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Sep 2024
- Primary completion
- Sep 2028
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and endostar in nasopharyngeal carcinoma (NPC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Overall Survival Rate at 3 years. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
camrelizumabendostar
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06611826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06611826.